Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoHKSE:09887 +8.04%10 PB Ratio is 10.61 as of Aug. 25, 2026, which is 19% above its 10-year median of 8.92. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,212 Biotechnology companies, Nanjing Leads Biolabs Co ranks worse than 87.29% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co PB Ratio Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
7.04
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PB Ratio
0.00
0.00
0.00
0.00
7.04
HKSE:09887 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nanjing Leads Biolabs Co (HKSE:09887) has a PB Ratio of 10.61 as of Aug. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nanjing Leads Biolabs Co and its competitors. This is 19% above median its historical median of 8.92. Over the past decade, Nanjing Leads Biolabs Co's PB Ratio has ranged from 7.05 to 13.08. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #1058 out of 1212 companies in the Biotechnology industry, placing it in the top 87.3%.
Is Nanjing Leads Biolabs Co's PB Ratio too high?
Nanjing Leads Biolabs Co's current PB Ratio of 10.61 is 19% above median its 10-year median of 8.92. Over the past 10 years, this metric has ranged from a low of 7.05 to a high of 13.08. The Biotechnology industry median PB Ratio is 2.96. Nanjing Leads Biolabs Co's value of 10.61 is 259.1% above this industry median. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #1058 out of 1212 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #1058 out of 1212 companies for PB Ratio. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median PB Ratio is 2.96. Nanjing Leads Biolabs Co's value of 10.61 is 259.1% above this benchmark. Historically, Nanjing Leads Biolabs Co's own PB Ratio has ranged from 7.05 to 13.08 over the past decade. While the company's 10-year median is 8.92 vs. the industry median of 2.96, Nanjing Leads Biolabs Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.96, based on 1,212 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Leads Biolabs Co's current PB Ratio of 10.61 is 259.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nanjing Leads Biolabs Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current PB Ratio is 10.61, which is 19% above median its own 10-year median of 8.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current PB Ratio of 10.61. The current PB Ratio is 10.61, which is 19% above median its 10-year median of 8.92 and 259.1% above the Biotechnology industry median of 2.96. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current PB Ratio is 10.61 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score
Get the complete analysis for HKSE:09887
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09887 has been successfully added to your 
